Literature DB >> 33608031

Urethral cancer managed with phallus preserving surgery: a case report.

Emily Walsh1, Niall Kelly2, Padraig Daly2, Nigam Shah3, Ivor Cullen2.   

Abstract

BACKGROUND: Primary urethral carcinoma (PUC) is rare and accounts for < 1% of all genito-urinary cancers. There is a male predominance of 3:1 and a peak incidence in the 7th and 8th decades. The aetiology of this cancer is similar to penile cancer, and the human papilloma virus (HPV) is thought to be an essential factor in tumorigenesis. Urethral cancer should be diagnosed and staged with a combination of tumour biopsy, MRI, and CT with treatment involving a multimodal approach. Contemporary management emphasises phallus-preserving surgery where feasible. CASE
PRESENTATION: Here, we describe a case of distal urethral carcinoma, which presented as a metastatic groin mass and identifying the primary lesion proved challenging. Diagnostic flexible cystoscopy identified a tiny lesion in the navicular fossa, which was biopsied and confirmed to be a squamous cell carcinoma. The patient then underwent phallus preserving surgery, including distal urethrectomy with bilateral inguinal lymph node dissections. The final stage was pT1N1M0, and adjuvant chemotherapy was started. The distal urethrectomy involved the surgical creation of a hypospadic meatus in the midshaft of the penis. Normal voiding and sexual function were preserved.
CONCLUSIONS: Urethral cancer is a rare malignancy and clinicians should bear in mind that early diagnosis of this disease can be very difficult depending on the anatomical location of the tumour. Treatment currently favours penis-preserving surgery.

Entities:  

Keywords:  Hypospadic neomeatus; Multi-modal therapy; Penis-preserving surgery; Urethral carcinoma

Mesh:

Year:  2021        PMID: 33608031      PMCID: PMC7896403          DOI: 10.1186/s13256-020-02553-z

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


  19 in total

Review 1.  Surgical treatment of carcinoma of the male urethra.

Authors:  E J Zeidman; P Desmond; I M Thompson
Journal:  Urol Clin North Am       Date:  1992-05       Impact factor: 2.241

2.  Integration of papillomavirus DNA near myc genes in genital carcinomas and its consequences for proto-oncogene expression.

Authors:  J Couturier; X Sastre-Garau; S Schneider-Maunoury; A Labib; G Orth
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

3.  Experience with primary carcinoma of the male urethra.

Authors:  B Ray; A R Canto; W F Whitmore
Journal:  J Urol       Date:  1977-05       Impact factor: 7.450

4.  Male urethral carcinoma: analysis of treatment outcome.

Authors:  G Dalbagni; Z F Zhang; L Lacombe; H W Herr
Journal:  Urology       Date:  1999-06       Impact factor: 2.649

5.  Primary carcinoma of the male urethra.

Authors:  J I Mandler; T L Pool
Journal:  J Urol       Date:  1966-07       Impact factor: 7.450

6.  Determination of telomerase activity in squamous cell carcinoma of the penis.

Authors:  G Alves; W Fiedler; E Guenther; P Nascimento; M M Campos; A A Ornellas
Journal:  Int J Oncol       Date:  2001-01       Impact factor: 5.650

Review 7.  EAU guidelines on primary urethral carcinoma.

Authors:  Georgios Gakis; J Alfred Witjes; Eva Compérat; Nigel C Cowan; Maria De Santis; Thierry Lebret; Maria J Ribal; Amir M Sherif
Journal:  Eur Urol       Date:  2013-04-02       Impact factor: 20.096

8.  Primary squamous cell carcinoma of anterior male urethra.

Authors:  K A Anderson; J W McAninch
Journal:  Urology       Date:  1984-02       Impact factor: 2.649

9.  Therapy and prognosis for male anterior urethral carcinoma: an update.

Authors:  C P Dinney; D E Johnson; D A Swanson; R J Babaian; A C von Eschenbach
Journal:  Urology       Date:  1994-04       Impact factor: 2.649

10.  Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus.

Authors:  Emmanuelle Ferreux; Anne P Lont; Simon Horenblas; Maarten P W Gallee; Frank M Raaphorst; Magnus von Knebel Doeberitz; Chris J L M Meijer; Peter J F Snijders
Journal:  J Pathol       Date:  2003-09       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.